Screener
Recursion Pharmaceuticals, Inc. RXRX Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | ||||
| Operating revenue | $7,303 | $19,103 | $13,605 | $33,921 |
| Grant revenue | 367 | 120 | 538 | 47 |
| Total revenue | 7,670 | 19,223 | 14,143 | 33,968 |
| Operating costs and expenses | ||||
| Cost of revenue | 11,491 | 20,161 | 23,981 | 41,990 |
| Research and development | 89,614 | 128,636 | 177,510 | 258,269 |
| General and administrative | 41,533 | 46,653 | 76,124 | 101,304 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s total revenue?
- Recursion Pharmaceuticals, Inc. (RXRX) reported total revenue of $7.67M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s total revenue changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s total revenue decreased by 60.1% year-over-year, from $19.22M to $7.67M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s total revenue?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s total revenue has grown at a 64.6% compound annual growth rate (CAGR), from $10.18M to $74.68M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Recursion Pharmaceuticals, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude